American Century Companies’s Structure Therapeutics GPCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$69.3M Buy
1,438,031
+931,072
+184% +$63.7M 0.04% 605
2025
Q4
$35.3M Buy
506,959
+20,173
+4% +$824K 0.02% 888
2025
Q3
$13.6M Sell
486,786
-4,407
-0.9% -$87.8K 0.01% 1307
2025
Q2
$10.2M Sell
491,193
-19,008
-4% -$418K 0.01% 1366
2025
Q1
$8.83M Sell
510,201
-102,415
-17% -$2.51M 0.01% 1366
2024
Q4
$16.6M Buy
612,616
+67,325
+12% +$2.39M 0.01% 1146
2024
Q3
$23.9M Buy
545,291
+110,309
+25% +$4.27M 0.01% 946
2024
Q2
$17.1M Buy
434,982
+173,523
+66% +$7.13M 0.01% 1031
2024
Q1
$11.2M Buy
+261,459
New +$11M 0.01% 1160

Other funds holding GPCR

American Century Companies's GPCR Position: Q1 2026 in Review

American Century Companies increased its Structure Therapeutics (GPCR) stake by 184% in Q1 2026, buying an estimated $63.7M and bringing the position to 1,438,031 shares worth $69.3M. The position accounts for 0.04% of the portfolio, ranked #605.

American Century Companies first reported a position in GPCR in Q1 2024 and has held it in 9 quarters since. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • American Century Companies held 1,438,031 shares of Structure Therapeutics worth $69.3M as of Q1 2026.
  • American Century Companies bought 931,072 Structure Therapeutics shares in Q1 2026, an estimated $63.7M.
  • Structure Therapeutics made up 0.04% of American Century Companies's portfolio in Q1 2026, its #605 holding.
  • American Century Companies first reported a position in Structure Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on American Century Companies's 13F filing for Q1 2026, filed 15 May 2026.